a.k.a. Brands Holding Corp. AKA 深 滬
已收盤 02-06 16:00:00 美东时间
10.59
+0.120
+1.15%
華盛通- 最 高10.745
- 今 開10.42
- 成交量 1255股
- 最 低 10.42
- 昨 收 10.47
- 總市值 1.14亿
- 52周最高 18.36
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 7.00
- 委 比 92.31%
- 總股本 1073.97万
- 歷史最高 182.76
- 量 比 0.35
- 振 幅 3.10%
- 歷史最低 3.60
- 每 手 1
- 風險率 2.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target
Small Cap Consumer Research analyst Eric M Beder reiterates a.k.a. Brands Holding (NYSE:AKA) with a Buy and maintains $30 price target.
2025-12-10 23:56
a.k.a. Brands Reports Q3 2025 Sales Decline
aka Brands Holding Corp ( ($AKA) ) has provided an announcement. a.k.a. Brands ...
2025-11-06 05:44
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
2025-10-30 14:22
Telsey Advisory Group Maintains Market Perform on a.k.a. Brands Holding, Maintains $13 Price Target
Telsey Advisory Group analyst Dana Telsey maintains a.k.a. Brands Holding (NYSE:AKA) with a Market Perform and maintains $13 price target.
2025-10-29 18:52
11 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
Gainers Fossil Group (NASDAQ:FOSL) shares increased by 51.3% to $4.01 during W...
2025-10-16 01:07
a.k.a. Brands' two-day rally runs out of steam
After surging more than 38% on Tuesday, shares of a.k.a. Brands (NYSE:AKA) are in retreat, returning nearly half of yesterday’s rally with volume continuing to trend more than twice the daily average....
2025-10-16 00:22
Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) rose sharply in p...
2025-10-14 17:45
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
2025-10-09 10:51
